

**Title:**

In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures

**Authors:**

Lea Wagmann, Lilian H. J. Richter, Tobias Kehl, Franziska Wack, Madeleine Pettersson Bergstrand, Simon D. Brandt, Alexander Stratford, Hans H. Maurer & Markus R. Meyer

This is a post-peer-review, pre-copyedit version of an article published in *Analytical and Bioanalytical Chemistry* (Volume 411, Pages 4751–4763(2019), DOI: 10.1007/s00216-018-1558-9

The final authenticated version is available online at: <https://doi.org/10.1007/s00216-018-1558-9>



1  
2  
3 **In vitro metabolic fate of nine LSD-based new psychoactive substances and**  
4 **their analytical detectability in different urinary screening procedures**  
5  
6  
7  
8  
9  
10

11 Lea Wagmann<sup>1</sup>, Lilian H. J. Richter<sup>1</sup>, Tobias Kehl<sup>1</sup>, Franziska Wack<sup>1</sup>,  
12 Madeleine Pettersson Bergstrand<sup>1,2,3</sup>, Simon D. Brandt<sup>4</sup>, Alexander Stratford<sup>5</sup>,  
13 Hans H. Maurer<sup>1</sup>, and Markus R. Meyer<sup>1</sup>  
14  
15  
16  
17  
18  
19

20  
21 <sup>1</sup> Department of Experimental and Clinical Toxicology, Institute of Experimental and  
22 Clinical Pharmacology and Toxicology, Center for Molecular Signaling (PZMS),  
23 Saarland University, Homburg, Germany  
24  
25

26  
27 <sup>2</sup> Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska  
28 Institutet, Stockholm, Sweden  
29

30  
31 <sup>3</sup> Department of Laboratory Medicine, Division of Clinical Chemistry, Karolinska  
32 Institutet, Stockholm, Sweden  
33  
34

35  
36 <sup>4</sup> School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University,  
37 Liverpool, UK  
38

39  
40 <sup>5</sup> Synex Synthetics BV, Maastricht, The Netherlands  
41

42  
43 ✉ Markus R. Meyer  
44 markus.meyer@uks.eu  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

The market of new psychoactive substances (NPS) is characterized by a high turnover and thus provides several challenges for analytical toxicology. The analysis of urine samples often requires detailed knowledge about metabolism given that parent compounds may either be present only in small amounts or may not even be excreted. Hence, knowledge of the metabolism of NPS is a prerequisite for the development of reliable analytical methods. The main aim of this work was to elucidate for the first time the pooled human liver S9 fraction metabolism of the nine *d*-lysergic acid diethylamide (LSD) derivatives 1-acetyl-LSD (ALD-52), 1-propionyl-LSD (1P-LSD), 1-butyryl-LSD (1B-LSD), *N*<sup>6</sup>-ethyl-nor-LSD (ETH-LAD), 1-propionyl-*N*<sup>6</sup>-ethyl-nor-LSD (1P-ETH-LAD), *N*<sup>6</sup>-allyl-nor-LSD (AL-LAD), *N*-ethyl-*N*-cyclopropyl lysergamide (ECPLA), (2'*S*,4'*S*)-lysergic acid 2,4-dimethylazetidide (LSZ), and lysergic acid morpholide (LSM-775) by means of liquid chromatography coupled to high resolution tandem mass spectrometry. Identification of the monooxygenase enzymes involved in the initial metabolic steps was performed using recombinant human enzymes and their contribution confirmed by inhibition experiments. Overall, *N*-dealkylation, hydroxylation, as well as combinations of these steps predominantly catalyzed by CYP1A2 and CYP3A4 were found. For ALD-52, 1P-LSD, and 1B-LSD deacylation to LSD was observed. The obtained mass spectral data of all metabolites is essential for reliable analytical detection particularly in urinalysis and for differentiation of the LSD-like compounds as biotransformations also led to structurally identical metabolites. However, in urine of rats after the administration of expected recreational doses and using standard urine screening approaches, parent drugs or metabolites could not be detected.

## KEYWORDS

Lysergamides, NPS, metabolism, urinalysis, LC-HRMS/MS

## Introduction

The discovery of the potent psychoactive effects of *d*-lysergic acid diethylamide (LSD, see Fig. 1) in 1943 triggered a new era in psychopharmacological research and subsequently became a household name in popular culture [1]. For the purpose of extending the knowledge of lysergamide-based structure-activity relationships, several LSD-based substances have been investigated [2-9]. In recent years, a renewed interest in the use of LSD within the clinical context emerged as documented by increasing numbers of studies involving human volunteers [10-12]. At the same time, a number of LSD-based substances appeared as 'research chemicals' on the new psychoactive substances (NPS) market, predominantly in the form of blotters and powders. These substances included 1-acetyl-LSD (ALD-52), 1-propionyl-LSD (1P-LSD) [13], 1-butyryl-LSD (1B-LSD), *N*<sup>6</sup>-ethyl-nor-LSD (ETH-LAD) [14], 1-propionyl-ETH-LAD (1P-ETH-LAD) [14], *N*<sup>6</sup>-allyl-nor-LSD (AL-LAD) [15], *N*-ethyl-*N*-cyclopropyl lysergamide (ECPLA) [16], (2'*S*,4'*S*)-lysergic acid 2,4-dimethylazetidide (LSZ) [15], and lysergic acid morpholide (LSM-775) [17] (Fig. 1).

NPS in general were reported to the EU Early Warning System at a rate of one per week in 2016 being a big issue in forensic or clinical toxicology and the health care system in general [18]. The ability to detect newly emerging drugs of abuse in samples obtained from biological matrices requires the development of reliable screening methods. Particularly the analysis of urine samples benefits from knowing the drug's metabolic transformation patterns, especially in cases where the parent compound may only be present in small amounts or not even be excreted. In case of LSD, its metabolite 2-oxo-3-hydroxy LSD was reported to be present at higher concentrations and detectable for a longer time than LSD itself in urine samples of LSD users [19]. The detection of 2-oxo-3-hydroxy LSD in urine has been subsequently described as part of some clinical investigations [20, 21]. In vivo studies in rodents or in vitro studies using human hepatocytes or human liver cell fractions such as pooled human liver microsomes (pHLM) or pooled human liver S9 (pS9) are established tools for metabolite formation and subsequent identification [22-25]. Several studies showed comparable metabolic profiles to human urine samples [26-28]. To date, no information on the phase I and II metabolism of the nine LSD derivatives investigated in this study is available. Therefore, the aim of the present study was first to identify the main in vitro phase I and II metabolites of ALD-52, 1P-LSD, 1B-LSD, ETH-LAD, 1P-ETH-LAD, AL-LAD, ECPLA, LSZ, and LSM-775 for toxicological screening purposes using pS9 incubations and subsequent analysis by liquid chromatography coupled to high resolution tandem mass spectrometry (LC-HRMS/MS). LSD was also investigated and results compared to literature

1  
2  
3 to aid development of the experimental conditions. In addition, the monooxygenase enzymes  
4 involved in the initial metabolic steps were investigated to assess the potential impact of  
5 interindividual variations that may occur during metabolism or as a consequence of drug-drug  
6 and drug-food interactions. As no information about the monooxygenases involved in the  
7 metabolism of LSD is available so far, it was also included in this study. Finally, detectability  
8 studies using rat urine collected after the administration of expected recreational doses of the  
9 LSD-based NPS and standard urine screening approaches (SUSAs) were conducted.

## 18 **Experimental**

### 21 **Chemicals and enzymes**

22  
23 ALD-52, 1P-LSD, 1B-LSD, ETH-LAD, 1P-ETH-LAD, AL-LAD, ECPLA, LSZ, and LSM-  
24 775 were available from previous studies and provided by Synex Synthetics (Maastricht, The  
25 Netherlands). LSD and LSD-d<sub>3</sub> were supplied by LGC Standards (Wesel, Germany).  
26 Isocitrate, isocitrate dehydrogenase, superoxide dismutase, 3'-phosphoadenosine-5'-  
27 phosphosulfate (PAPS), S-(5'-adenosyl)-L-methionine (SAM), dithiothreitol (DTT), reduced  
28 glutathione (GSH), carnitine acetyltransferase, acetylcarnitine, acetyl coenzyme A (AcCoA),  
29 magnesium chloride (MgCl<sub>2</sub>), potassium dihydrogenphosphate (KH<sub>2</sub>PO<sub>4</sub>), dipotassium  
30 hydrogenphosphate (K<sub>2</sub>HPO<sub>4</sub>), Tris hydrochloride, ketoconazole, and alpha-naphthoflavone  
31 from Sigma-Aldrich (Taufkirchen, Germany), and NADP<sup>+</sup> were from Biomol (Hamburg,  
32 Germany). Acetonitrile (LC-MS grade), ammonium formate (analytical grade), formic acid  
33 (LC-MS grade), methanol (LC-MS grade), and all other chemicals and reagents (analytical  
34 grade) were from VWR (Darmstadt, Germany). The baculovirus-infected insect cell  
35 microsomes (Supersomes) containing 1 nmol/mL of human cDNA-expressed CYP1A2,  
36 CYP2A6, CYP2B6, CYP2C8, CYP2C9 (2 nmol/mL), CYP2C19, CYP2D6, CYP2E1  
37 (2 nmol/mL), CYP3A4, CYP3A5 (2 nmol/mL), or FMO3 (5 mg protein/mL), and pHLM  
38 (20 mg microsomal protein/mL, 330 pmol total CYP/mg protein), pS9 (20 mg microsomal  
39 protein/mL), UGT reaction mixture solution A (25 mM UDP-glucuronic acid), and UGT  
40 reaction mixture solution B (250 mM Tris HCl, 40 mM MgCl<sub>2</sub>, and 125 µg/mL alamethicin)  
41 were obtained from Corning (Amsterdam, The Netherlands). After delivery, the enzymes and  
42 liver cell preparations were thawed at 37 °C, aliquoted, snap-frozen in liquid nitrogen, and  
43 stored at -80 °C until use. LSD and all other lysergamide test drugs were dissolved in  
44 methanol at a concentration of 1 mg/mL, each, and stored at -20 °C.

### **In vitro incubations for metabolism studies**

As previously described by Richter et al. [29], the final incubation volume was 150  $\mu\text{L}$ . Incubations were performed using pS9 (2 mg microsomal protein/mL) after preincubation for 10 min at 37  $^{\circ}\text{C}$  with 25  $\mu\text{g}/\text{mL}$  alamethicin (UGT reaction mixture solution B), 90 mM phosphate buffer (pH 7.4), 2.5 mM  $\text{Mg}^{2+}$ , 2.5 mM isocitrate, 0.6 mM  $\text{NADP}^{+}$ , 0.8 U/mL isocitrate dehydrogenase, 100 U/mL superoxide dismutase, 0.1 mM AcCoA, 2.3 mM acetylcarnitine, and 8 U/mL carnitine acetyltransferase. Thereafter, 2.5 mM UDP-glucuronic acid (UGT reaction mixture solution A), 40  $\mu\text{M}$  PAPS, 1.2 mM SAM, 1 mM DTT, 10 mM GSH, and 25  $\mu\text{M}$  substrate (LSD or analog) were added. All given concentrations are the final concentrations in one reaction tube. The organic solvent content in the final incubation mixtures was always below 1% [30]. The reaction was initiated by addition of substrate and the reaction mixture was incubated for a maximum of 480 min. After 60 min, an aliquot of 60  $\mu\text{L}$  of the incubation mixture was transferred to a reaction tube containing 20  $\mu\text{L}$  ice-cold acetonitrile for termination of the reactions. The remaining mixture was incubated for additional 420 min and thereafter stopped by addition of 30  $\mu\text{L}$  ice-cold acetonitrile. Afterwards, mixtures were cooled for 30 min at -18  $^{\circ}\text{C}$ , centrifuged for 2 min at 10.000 x g, and a volume of 60  $\mu\text{L}$  of the supernatants transferred into autosampler vials, followed by injection of 1  $\mu\text{L}$  onto the LC-HRMS/MS system. Blank samples without substrate and control samples without pS9 were prepared to confirm the absence of interfering compounds and to identify compounds not formed by metabolism, respectively. All incubations were performed in duplicates ( $n = 2$ ).

### **Monoxygenases activity screening and inhibition studies using selective CYP inhibitors**

According to previously published procedures [31], microsomal incubations ( $n = 2$  each) were performed at 37  $^{\circ}\text{C}$  for 30 min using a substrate concentration of 25  $\mu\text{M}$  (LSD or analog) and CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5 (75 pmol/mL each), or FMO3 (0.25 mg protein/mL). Reference incubations with pHLM (1 mg microsomal protein/mL) were used as positive control. Control samples without enzymes were prepared to assess formation of compounds that did not originate from metabolism. Besides enzymes and substrates, the incubation mixtures (final volume, 50  $\mu\text{L}$ ) contained 90 mM phosphate buffer (pH 7.4), 5 mM  $\text{Mg}^{2+}$ , 5 mM isocitrate, 1.2 mM  $\text{NADP}^{+}$ ,

0.5 U/mL isocitrate dehydrogenase, and 200 U/mL superoxide dismutase. For incubations with CYP2A6 or CYP2C9, phosphate buffer was replaced with 90 mM Tris buffer, respectively, according to the manufacturer's recommendation. Reactions were initiated by addition of the enzyme preparation and terminated by addition of 50  $\mu$ L of ice-cold acetonitrile, containing 5  $\mu$ M LSD-d<sub>3</sub> as internal standard. The mixture was centrifuged for 2 min at 18,407 x g (rcf). Seventy  $\mu$ L of the supernatant were transferred into an autosampler vial and 1  $\mu$ L was injected onto the LC-HRMS/MS system.

According to a previous study [32], the influence of ketoconazole (CYP3A4 inhibitor), alpha-naphthoflavone (CYP1A2 inhibitor), or a mixture of them (1  $\mu$ M, respectively) on the formation of monooxygenase-dependent metabolites was assessed using pHLM (1 mg microsomal protein/mL), 25  $\mu$ M substrate (LSD or one of the analogs), and LSD-d<sub>3</sub> as internal standard. All incubations were performed at 37 °C for 20 min with six replicates in each test set. All other incubation settings were the same as described for the monooxygenase activity screening. As measure of the metabolite formation in reference incubations without inhibitor, peak areas of all metabolites were summed up and divided by the peak area of the internal standard. This was also done for control incubations without pHLM and peak area ratios were subtracted from that in reference incubations. The result was referred to as 100% and compared to peak area ratios in test incubations with inhibitor. Significance of inhibition was tested using a one-way ANOVA followed by Dunnett's multiple comparison test (significance level,  $P < 0.001$ , 99.9% confidence intervals) by GraphPad Prism 5.00 software (GraphPad Software, San Diego, USA).

### LC-HRMS/MS instrumentation

A Thermo Fisher Scientific (TF, Dreieich, Germany) Dionex UltiMate 3000 Rapid Separation (RS) UHPLC system with a quaternary UltiMate 3000 RS pump and an UltiMate 3000 RS autosampler was used, controlled by the TF Chromeleon software version 6.80, and coupled to a TF Q-Exactive Plus equipped with a heated electrospray ionization II source (HESI-II). Mass calibration was performed prior to analysis according to the manufacturer's recommendations using external mass calibration. Gradient elution was performed on a TF AccuCore PhenylHexyl column (100 mm x 2.1 mm inner diameter, 2.6  $\mu$ m particle size). The mobile phases consisted of 2 mM aqueous ammonium formate containing formic acid (0.1%, v/v) and acetonitrile (1%, v/v, pH 3, eluent A) and 2 mM ammonium formate in acetonitrile/methanol (50:50, v/v) containing formic acid (0.1%, v/v) and water (1%, v/v,

1  
2  
3 eluent B). The gradient and flow rate were programmed as follows: 0-10 min 10% B to 50%  
4 B, 10-12 min hold 98% B, and 12-14 min hold 10% B, constantly at a flow rate of  
5 0.5 mL/min. HESI-II conditions have been employed as described previously by Wagmann et  
6 al. [33]: heater temperature, 438 °C; ion transfer capillary temperature, 269 °C; sheath gas, 53  
7 arbitrary units (AU); auxiliary gas, 14 AU; sweep gas, 3 AU; spray voltage, 3.50 kV, and S-  
8 lens RF level, 60.0. Mass spectrometric analysis was performed in positive full scan mode  
9 and targeted MS<sup>2</sup> mode using an inclusion list. Pick others mode was activated to ensure the  
10 recording of MS<sup>2</sup> spectra of precursor ions not in the inclusion list. The settings for full scan  
11 data acquisition were as follows: resolution, 35 000; automatic gain control (AGC) target,  
12 1e6; maximum injection time (IT), 120 ms; scan range, *m/z* 100-700. The settings for the  
13 targeted MS<sup>2</sup> mode using an inclusion list were as follows: resolution, 17 500; AGC target,  
14 2e5; maximum IT, 250 ms; isolation window, *m/z* 1.0; high collision dissociation cell with  
15 stepped normalized collision energy, 17.5, 35.0, 52.5. TF Xcalibur Qual Browser software  
16 version 2.2 SP1.48 was used for data evaluation.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

### 31 **Collection of rat urine samples for detectability studies**

32  
33 In accordance to previous publications [34], the in vivo studies were performed using rat  
34 urine samples from male Wistar rats (Charles River, Sulzfeld, Germany) for toxicological  
35 diagnostic reasons according to corresponding German law (Bundesministerium der Justitz  
36 und für Verbraucherschutz, <http://www.gesetze-im-internet.de/tierschg/index.html>). Before  
37 drug administration, blank urine was collected over a period of 24 h. Animals had water *ad*  
38 *libitum* during collection of urine over a 24 h period and were housed in a metabolism cage.  
39 Urine was collected separated from feces. For the detectability studies, doses of 0.01 mg/kg  
40 body weight (BW) were administered. The urine samples were analyzed directly and  
41 remaining was aliquoted and stored at -20 °C.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

### 52 **Rat urine analysis by LC-HRMS/MS, LC-linear ion trap MS, and gas chromatography- 53 MS**

54  
55  
56 To check the detectability and analytical differentiation of the LSD-based NPS after estimated  
57 recreational user's dose administrations, three SUSAs were performed. The settings were  
58 used as described in the given references for the LC-HRMS/MS [35], LC linear ion trap MS  
59  
60



(LC-MS<sup>n</sup>) [36, 37], and gas chromatography (GC)-MS [38, 39] SUSAs. Briefly, the following sample preparations were used: a simple urine precipitation with acetonitrile for the LC-based SUSAs and a liquid-liquid extraction after acidic hydrolysis followed by and acetylation for the GC-MS SUSAs. Detection limits for LSD and its derivatives by the aforementioned methods was studied using methanolic pure substance solutions at various concentrations (0.1, 1, 10, and 100 ng/mL). The lowest concentration resulting in an MS<sup>2</sup> spectrum was defined as limit of identification (LOI).

## Results and discussion

### Identification of metabolites

Human metabolites of LSD were already described [19, 40-43]. To confirm suitable incubation conditions and detection methods concerning the in vitro assay, LSD was also incubated with pS9 and analyzed by LC-HRMS/MS. In general, MS<sup>1</sup> data was screened for potential exact precursor masses (PM) of expected metabolites. Afterwards, the fragmentation pattern in the MS<sup>2</sup> spectrum was interpreted and compared to that of the parent compound for confirmation and possible assignment of the position. This procedure was the same for LSD and its analogs.

The lysergamide test drugs and all identified phase I and II metabolites are listed in Table 1, which contains their ID, the calculated exact mass of the protonated precursor (M+H<sup>+</sup>), elemental composition, determined retention time (RT) and three most abundant fragment ions (FI) in MS<sup>2</sup>. In total, the pS9 incubations resulted in detection of several tentative metabolites. LSD: six metabolites; ALD-52: seven metabolites; 1P-LSD: eight metabolites; 1B-LSD: seven metabolites; ETH-LAD: five metabolites; 1P-ETH-LAD: seven metabolites; AL-LAD: eleven metabolites; ECPLA: eight metabolites; LSZ: nine metabolites, and LSM-775: four metabolites.

The LSD metabolites were comparable to those described before: *N*-deethyl LSD (ID 2, also referred to as lysergic acid monoethylamide, LAE) and *N*<sup>6</sup>-demethyl LSD (ID 3, also referred to as nor-LSD) could be unambiguously identified. Two hydroxy LSD isomers were detected, but it has to be stated that the final positions of the hydroxy groups could not be determined based on fragmentation patterns. However, hydroxy LSD isomer 2 (ID 5) and the corresponding glucuronide (ID 7) are expected to be the same as described by Steuer et al. in plasma samples [42] based on their fragmentation. Dihydroxy LSD (ID 6) is expected to be the same compound referred to as 2-oxo-3-hydroxy LSD elsewhere, which is widely known

1  
2  
3 as main metabolite of LSD [19, 20, 44-46]. Only the hydroxy LSD isomer with the hydroxy  
4 group located at the diethylamide part of the molecule (also referred to as lysergic acid ethyl-  
5 hydroxy ethylamide, LEO) and trihydroxy LSD were described to be present as minor signals  
6 in human plasma or urine but not detected in the in vitro pS9 incubations. However, it should  
7 be kept in mind that quantitative determinations of the metabolites' concentrations were  
8 beyond the scope of this study. Under the investigated conditions, these two metabolites  
9 might have been formed in concentrations below detectability or the chosen incubation time  
10 was not sufficient for their formation, as multistep reactions were already described to need a  
11 longer incubation time [47]. Furthermore, LSD hydroxy isomer 1 (ID 4) was expected to be  
12 hydroxylated in position 4 or 5 due to the fragmentation pattern, which was not described  
13 before (discussed in detail below for 1-depropionyl hydroxy 1P-LSD isomer 1, ID 4). Iso-  
14 LSD, a diastereomer of LSD, which is formed during the production of LSD under basic  
15 conditions, was previously used as additional marker for LSD consumption and shown to be  
16 metabolized in the human body. The spectra of LSD and iso-LSD differed only in the  
17 intensity of particular FI [42]. For several LSD-based NPS, a smaller signal with the same  
18 mass could be detected eluting after the parent compound. The MS<sup>2</sup> only showed differences  
19 in the intensity of some FI and therefore, these signals were expected to be generated by the  
20 iso-forms. However, due to the lack of reference material, their identity could not be  
21 confirmed.

22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36 Due to the large number of LSD-based drugs used during this study, some  
37 representative examples were chosen to illustrate the general identification procedure.  
38 Furthermore, all compounds and their metabolites showed comparable fragmentation patterns.  
39 The procedure used for the tentative identification of the metabolites based on the HRMS/MS  
40 spectra was employed according to the example described for 1P-LSD (ID 11). Brandt et al.  
41 previously published an MS<sup>2</sup> spectrum of 1P-LSD recorded using electrospray ionization  
42 accurate mass quadrupole time of flight tandem mass spectrometry [13]. The observed  
43 fragmentation pattern corresponded to the MS<sup>2</sup> spectrum of 1P-LSD using orbitrap-based  
44 tandem mass spectrometry. The MS<sup>2</sup> spectra of LSD (ID 1) and 1P-LSD (ID 11) can be found  
45 in Fig. 2. Briefly, the FI at  $m/z$  337.1910 ( $C_{21}H_{25}N_2O_2^+$ ) formed after loss of *N*-  
46 methylmethanimine ( $C_2H_5N$ ) and the FI at  $m/z$  279.1491 ( $C_{18}H_{19}N_2O^+$ ) formed after loss of  
47 *N,N*-diethylformamide ( $C_5H_{11}NO$ ) from the protonated molecule ( $C_{23}H_{30}N_3O_2^+$ ) were  
48 characteristic for 1P-LSD and allowed for a differentiation of the MS<sup>2</sup> spectrum of LSD since  
49 both FI carried the additional 1-propionyl moiety ( $C_3H_5O$ ). These FI correspond to the FI at  
50  $m/z$  281.1648 ( $C_{18}H_{21}N_2O^+$ ) and at  $m/z$  223.1229 ( $C_{15}H_{15}N_2^+$ ) detected in the MS<sup>2</sup> spectrum of  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

LSD (Fig. 2). The last-named FI ( $m/z$  223.1229) represented the  $N^6$ -methylated 9,10-didehydroergoline core and was the FI with the highest abundance in the MS<sup>2</sup> spectrum of 1P-LSD, most probably formed after elimination of the  $N^1$ -propionyl moiety from the FI at  $m/z$  279.1491. Also, the FI at  $m/z$  208.0756 ( $C_{14}H_{10}NO^+$ ) had a high abundance and was also detectable in the MS<sup>2</sup> spectrum of LSD. However, it has to be mentioned that a second FI with the nominal mass of  $m/z$  208 but the exact mass of at  $m/z$  208.0995 ( $C_{14}H_{12}N_2^+$ ) was detectable with a comparable abundance to 208.0756 in both spectra, which was most probably formed after loss of methyl ( $CH_3$ ) from FI at  $m/z$  223.1229. In addition, the FI at  $m/z$  128.1069 ( $C_7H_{14}NO^+$ ) and  $m/z$  74.0964 ( $C_4H_{12}N^+$ ) representing the diethylamide part were detectable in the spectra of 1P-LSD and LSD. The HRMS/MS spectra of all parent compounds and the most abundant, unique metabolites after pS9 incubation allowing the identification of the parent compound (with exception of the ETH-LAD metabolite that could also be formed after intake of 1P-ETH-LAD) can be found in the electronic supplementary material in Fig. S1.

In total, eight metabolites of 1P-LSD were identified in the pS9 incubations (see Table 1). 1-Depropionylation led to the formation of LSD (ID 1, PM at  $m/z$  324.2070). Therefore, 1P-LSD can be considered as LSD prodrug, which was consistent with preliminary data reported by Brandt et al. who incubated 1P-LSD in human serum [13]. An additional  $N$ -deethylation led to formation of 1-depropionyl- $N$ -deethyl 1P-LSD (ID 2, PM at  $m/z$  296.1757). The loss of an ethylene group (- 28.0313 u,  $C_2H_4$ ) resulted in the FI at  $m/z$  253.1335 ( $C_{16}H_{17}N_2O^+$ ) in comparison to  $m/z$  281.1648 in the MS<sup>2</sup> spectrum of LSD. Other FI, for example at  $m/z$  223.1229 or  $m/z$  208.0756 remained unchanged, whereas the FI at  $m/z$  74.0964 was not detectable in the MS<sup>2</sup> spectrum of 1-depropionyl- $N$ -deethyl 1P-LSD (ID 2).  $N^6$ -demethylation instead of  $N$ -deethylation resulted in formation of 1-depropionyl- $N^6$ -demethyl 1P-LSD (ID 3, PM at  $m/z$  310.1913). The FI at  $m/z$  223.1229 was shifted to  $m/z$  209.1073 ( $C_{14}H_{13}N_2^+$ ) corresponding to the loss of methylene (- 14.0156 u,  $CH_2$ ). Other FI, for example at  $m/z$  281.1648 or  $m/z$  74.0964 were unchanged compared to LSD. Two isomers of 1-depropionyl-hydroxy 1P-LSD (ID 4 and 5, PM at  $m/z$  340.2019) were detectable. In the MS<sup>2</sup> spectrum of isomer 1 (ID 4, RT 3.4 min, Fig. 2), an initial loss of water (- 18.0105 u,  $H_2O$ ) was detectable. Therefore, 1-depropionyl-hydroxy 1P-LSD isomer 1 was expected to carry an aliphatic hydroxy group. Based on the fragmentation pattern, a hydroxylation at the diethylamide part can be excluded because the FI at  $m/z$  74.0964 was present in the MS<sup>2</sup> spectrum. Due to the detection of  $m/z$  297.1597 ( $C_{18}H_{21}N_2O_2^+$ ), a hydroxylation at the  $N^6$ -methyl group and position 7 can be excluded, which led to the indication that the hydroxy

group might have been located at position 4 or 5. However, an unambiguous assignment was not possible based on the fragmentation pattern in the MS<sup>2</sup> spectrum. In case of 1-depropionyl-hydroxy 1P-LSD isomer 2 (ID 5, RT 3.6 min) no water loss was detectable and the hydroxy group should therefore most likely be located at an aromatic position [48]. The FI at  $m/z$  74.0964 and  $m/z$  297.1597 were both present. Due to these FI, the hydroxy group is most probably located at the indole part of the 9,10-didehydroergoline core. Furthermore, 1-depropionyl-dihydroxy 1P-LSD (ID 6, PM at  $m/z$  356.1968) was detected with one aliphatic and one aromatic hydroxy group. Due to the fragmentation pattern, this metabolite could be the result of the combination of both monohydroxy isomers (ID 4 and 5). However, the metabolite 2-oxo-3-hydroxy LSD was reported to be the main urinary excretion product of LSD [19, 41]. Possible metabolic pathways resulting in its formation were discussed by Klette et al. [40]. Nevertheless, its protonated mass at  $m/z$  356 corresponds to the mass of 1-depropionyl-dihydroxy 1P-LSD (ID 6). Also the prominent FI at  $m/z$  237 and  $m/z$  338 described by Klette et al. were present in the spectrum of 1-depropionyl-dihydroxy 1P-LSD (ID 6). Due to this fact and the proposed fragmentation pattern, both compounds were expected to be identical. The aforementioned metabolites of 1P-LSD were also found in incubations with LSD and are therefore not suitable as urinary markers to discriminate between the intake of LSD and 1P-LSD. In general, structurally identical metabolites have the same ID in Table 1 to highlight these observations. Nevertheless, two 1P-LSD metabolites not evolved from LSD were identified. These metabolites were formed from 1P-LSD by *N*-deethylation (ID 12, PM at  $m/z$  352.2019) and *N*<sup>6</sup>-demethylation (ID 13, PM at  $m/z$  366.2176), respectively. In case of *N*-deethyl 1P-LSD (ID 12, Fig. 2), the FI at  $m/z$  309.1597 ( $C_{19}H_{21}N_2O_2^+$ ) corresponded to the FI at  $m/z$  337.1910 in the spectrum of 1P-LSD shifted by -28.0313 u, the loss of an ethylene group ( $C_2H_4$ ). The FI at  $m/z$  279.1491 was unchanged. In case of *N*<sup>6</sup>-demethyl 1P-LSD (1P-nor-LSD) (ID 13), the FI at  $m/z$  279.1491 was shifted by -14.0156 u due to the loss of methylene ( $CH_2$ ) while the FI at  $m/z$  337.1910 was unchanged. However, it is possible that *N*<sup>6</sup>-demethyl 1P-LSD (ID 13) was also generated during the metabolic transformation of 1P-ETH-LAD although it was not detected in the pS9 incubations. In conclusion, *N*-deethyl 1P-LSD (ID 12) was the only metabolite that could only be formed from 1P-LSD and from no other LSD-type NPS investigated in this study. LSD could also be formed after intake of ALD-52 or 1B-LSD and in both cases, LSD and its metabolites were detected in the pS9 incubations. In case of ALD-52, the two specific metabolites *N*-deethyl ALD-52 (ID 9, PM at  $m/z$  338.1863) and *N*<sup>6</sup>-demethyl ALD-52 (nor-ALD-52) (ID 10, PM at  $m/z$  352.2019) were additionally identified and in case of 1B-LSD,

1  
2  
3 only hydroxy 1B-LSD (ID 15, PM at  $m/z$  410.2438) was detected. These findings clearly  
4 demonstrated that urinary screening results have to be interpreted with care and that a positive  
5 urine screening result for LSD or its metabolites must not always be caused by an intake of  
6 LSD itself.  
7  
8  
9

### 10 11 12 13 **Proposed metabolic pathways**

14  
15  
16 The proposed metabolic pathways of 1P-LSD are given in Figure 3. The proposed metabolic  
17 pathways and MS<sup>2</sup> data of the other compounds can be found in the electronic supplementary  
18 material (Fig. S1-S10).  
19  
20  
21  
22  
23

### 24 25 **Monooxygenases activity screening and inhibition studies using selective CYP inhibitors**

26  
27 In order to investigate the ability of monooxygenases to catalyze the initial metabolic phase I  
28 steps, an activity screening study using the ten most important CYP isoenzymes and FMO3  
29 was performed. Incubations with pHLM were used as control. These data are only qualitative  
30 and do not reflect a quantitative contribution of the investigated monooxygenases to hepatic  
31 clearance. Such an assessment requires the collection of enzyme kinetic data or inhibition  
32 experiments [31, 32, 49]. Results are listed in Table 2. CYP3A4 was found to be involved in  
33 the *N*<sup>6</sup>-demethylation of LSD, ALD-52, 1P-LSD, 1B-LSD, ECPLA, LSZ, and LSM-775, but  
34 also in the *N*<sup>6</sup>-deethylation of ETH-LAD and 1P-ETH-LAD and *N*<sup>6</sup>-deallylation of AL-LAD.  
35 Only in case of LSD, CYP2C19 showed additional *N*<sup>6</sup>-demethylation activity. CYP3A4 also  
36 catalyzed the *N*-deethylation of LSD and all other lysergamide test drugs, which resulted in  
37 the formation of *N*-mono ethylamide analog. Only CYP2C9 also catalyzed the *N*-deethylation  
38 of LSD and ECPLA. Aliphatic or aromatic hydroxylations were also catalyzed by CYP3A4  
39 for all investigated test drugs and additionally by CYP1A2 with the exception of the 1-  
40 acylated LSD derivatives and ETH-LAD. CYP2D6 was found to be involved in the  
41 hydroxylation of ALD-52, 1B-LSD, and ETH-LAD. In pHLM incubations, the 1-deacylation  
42 of ALD-52, 1P-LSD, 1B-LSD, and 1P-ETH-LAD was additionally observed. However, this  
43 step was expected to be catalyzed by amidases and was not observed in incubations with the  
44 recombinant monooxygenases. In pHLM incubations with AL-LAD, ECPLA, and LSZ, also  
45 the corresponding lysergic acid metabolite was detected, and in case of ECPLA and LSZ, also  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 lysergic acid amide. However, these metabolites could not be detected in incubations with  
4 recombinant enzymes and may also be the result of amidase-catalyzed reactions.

5  
6 The involvement of CYP1A2 and especially CYP3A4 in the metabolism of the investigated  
7 lysergamides is noteworthy. To confirm these results and to assess the importance of their  
8 contribution to the metabolism of these substances in the human liver, pHLM incubations in  
9 presence of selective CYP inhibitors were performed [32]. LSD, 1B-LSD, ETH-LAD, AL-  
10 LAD, ECPLA, LSZ, and LSM-775 were incubated with the CYP1A2 inhibitor alpha-  
11 naphthoflavone, the CYP3A4 inhibitor ketoconazole or a mixture of them. For ALD-52, 1P-  
12 LSD, 1B-LSD, ETH-LAD, and 1P-ETH-LAD, only ketoconazole was used **because only**  
13 **CYP3A4 was shown to be involved in their initial metabolic steps**. Results are summarized in  
14 Figure 4. Formation of CYP-dependent metabolites in reference incubations without inhibitor  
15 were set to 100% and compared to metabolite formation in incubations with inhibitor. For all  
16 test drugs, a significant reduction of metabolite formation in incubations with inhibitors was  
17 observed. In case of LSD, co-incubations with alpha-naphthoflavone decreased the metabolite  
18 formation by more than 50% and with ketoconazole and a mixture of both inhibitors by more  
19 than 80% in comparison to the incubations without inhibitor. Metabolite formation in co-  
20 incubations of the 1-acylated lysergamides (ALD-52, 1P-LSD, 1B-LSD, and 1P-ETH-LAD)  
21 with ketoconazole was reduced by more than 80%. In case of ETH-LAD, ketoconazole led to  
22 a reduction of the metabolite formation by around 70%. The formation of AL-LAD, ECPLA,  
23 and LSZ metabolites was significantly increased by both inhibitors, alpha-naphthoflavone and  
24 ketoconazole, and co-incubations with their mixture resulted in a decrease of more than 70%  
25 in case of AL-LAD and around 90% for ECPLA and LSZ. Only in case of LSM-775, co-  
26 incubations with alpha-naphthoflavone did not result in a statistically significant reduction of  
27 formed metabolites, in contrast to co-incubations with ketoconazole and their mixture that led  
28 to decreased metabolite formation of around 70% or 80%, respectively. Residual metabolite  
29 formations were most probably caused by incomplete enzyme inhibition and/or the  
30 involvement of further CYP isoforms in the metabolic transformation of the test drugs.  
31 Nevertheless, the inhibition experiments confirmed the importance of CYP1A2 and especially  
32 CYP3A4 in the metabolism of LSD analogs. CYP1A2 is known to be expressed  
33 polymorphically in humans, resulting in large interindividual variation of activity [50]. For  
34 example, polymorphisms resulting in lower CYP1A2 activity may lead to a decreased  
35 metabolic transformation of LSD-like substances that could result in an increased half-life of  
36 the drug. However, the results of the inhibition experiments suggest that CYP3A4 is even  
37 more important in the metabolism of LSD-related substances. Inhibition of CYP3A4 by co-  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 consumed drugs or food ingredients may also lead to decreased metabolic transformation.  
4 Nevertheless, LSD is not expected to exhibit remarkable acute toxicity [51, 52], but nothing is  
5 known about the toxicity of the LSD-based NPS.  
6  
7  
8  
9  
10

### 11 **Toxicological detectability**

12  
13  
14 For toxicological detectability studies, a dose of 0.01 mg/kg BW was administered to rats.  
15 Assuming a human BW of 60 kg, the doses corresponded to an expected recreational dose of  
16 136 µg in accordance to the dose by factor approach [53]. The SUSAs by GC-MS, LC-MS<sup>n</sup>,  
17 and LC-HRMS/MS were used and the results are briefly described in the following.  
18  
19  
20  
21  
22  
23

#### 24 *GC-MS standard urine screening approach*

25  
26  
27 No metabolites or parent compounds could be identified in the rat urine by the GC-MS  
28 SUSAs. This was most probably caused by the low stability of LSD and its derivatives against  
29 acidic hydrolysis and heat [54]. Nevertheless, the sample preparation was not changed as this  
30 is an established procedure used in toxicological routine analysis [55, 39]. Other reason could  
31 be minor excretion in rat urine and/or insufficient sensitivity of the used GC-MS apparatus.  
32 Also at and below 100 ng/mL of methanolic pure substance solutions, the GC-MS procedure  
33 was not able to detect the analytes.  
34  
35  
36  
37  
38  
39  
40  
41  
42

#### 43 *LC-MS<sup>n</sup> standard urine screening approach*

44  
45 No metabolites or parent compounds could be identified in the rat urine by the LC-MS<sup>n</sup>  
46 SUSAs. most probably caused by insufficient sensitivity. The LOIs using methanolic pure  
47 substance solutions were as follows: 1 ng/mL for 1P-LSD, 10 ng/mL for LSD, ALD-52,  
48 ETH-LAD, AL-LAD, ECPLA, LSZ, and LSM-775, and 100 ng/mL for 1B-LSD and 1P-  
49 ETH-LAD. One reason for the lack of sensitivity might be the extremely broad peaks under  
50 the used standard conditions.  
51  
52  
53  
54  
55  
56  
57  
58

#### 59 *LC-HRMS/MS standard urine screening approach*

1  
2  
3 Only a single ALD-52 metabolite, 1-deacetyl-*N*-deethyl ALD-52 (ID 2), was identified in the  
4 rat urine samples after a recreational user's dose. However, this metabolite is not unique and  
5 can also be formed after intake of LSD, 1P-LSD, or 1B-LSD. No other metabolites or parent  
6 compounds could be identified by the LC-HRMS/MS SUSA. The LOIs using methanolic  
7 pure substance solutions were as follows: 1 ng/mL for LSD, 1P-LSD, ETH-LAD, AL-LAD,  
8 ECPLA, and LSZ, and 10 ng/mL for ALD-52, 1B-LSD, 1P-ETH-LAD, and LSM-775.  
9

10  
11  
12 Therefore, for detection and differentiation of an intake of LSD or its derivatives after  
13 expected recreational doses, a more selective sample workup, concentration step, and more  
14 selective MS settings, may help in detecting the parent drugs and/or unique metabolites  
15 identified in this study. For example solid-phase extraction by mixed-mode cartridges,  
16 optionally after enzymatic conjugate cleavage, followed by LC-HRMS/MS using an adapted  
17 separation method and selective product ion scan or multiple-reaction monitoring should meet  
18 these requests.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

## 29 Conclusions

30  
31 The present study demonstrated that ALD-52, 1P-LSD, 1B-LSD, ETH-LAD, 1P-ETH-LAD,  
32 AL-LAD, ECPLA, LSZ, and LSM-775 were biotransformed to several phase I and few phase  
33 II metabolites in vitro. Many metabolites can originate from different parent compounds  
34 making their differentiation difficult, but this study also identified unique metabolites  
35 overcoming this problem. The mass spectral data obtained during these studies is essential for  
36 establishing reliable detection methods, especially for urinalysis. However, selective sample  
37 workup and MS settings are needed for reliable analytical detection and differentiation.  
38 CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 were found to be involved in the  
39 initial metabolic steps. Inhibition experiments confirmed the major influence of CYP1A2 and  
40 CYP3A4, therefore genetic polymorphisms of CYP1A2 might have an impact on the  
41 metabolism of these NPS. Furthermore, drug-drug or drug-food interactions might occur in  
42 case of co-consumption with CYP1A2 or CYP3A4 inhibitors resulting in decreased metabolic  
43 transformation of LSD analogs, but further investigations are needed for an assessment of  
44 possible clinical effects. The authors' standard urine screening procedures are most likely not  
45 able to allow the detection of the studied NPS. Alternative analytical strategies need to be  
46 used instead.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



### **Acknowledgement**

The authors would like to thank Armin A. Weber and the “Stiftelsen för Klinisk farmakologi & farmakoterapi” for support.

### **Compliance with ethical standards**

Conflict of interest: The authors declare that there are no conflicts of interest.

### **Electronic supplementary material**

Electronic supplementary material may be found online.

**Table 1:** LSD, ALD-52, 1P-LSD, 1B-LSD, **ETH-LAD, 1P-ETH-LAD, AL-LAD, ECPLA, LSZ, LSM-775, and** their phase I and II metabolites along with their identification numbers (ID), the exact mass of the protonated molecule ( $M+H^+$ ), elemental composition, retention time (RT), and the three most abundant fragment ions (FI A-C) in MS<sup>2</sup> sorted by decreasing intensity. The parent compounds are given in bold and the metabolites were sorted by increasing mass and RT.

ID	Compound	Exact mass, $m/z$	Elemental composition	RT, min	FI A	FI B	FI C
<b>1</b>	<b>LSD</b>	<b>324.2070</b>	<b>C<sub>20</sub>H<sub>26</sub>N<sub>3</sub>O</b>	<b>5.3</b>	<b>223.1229</b>	<b>208.0995</b>	<b>281.1648</b>
2	<i>N</i> -Deethyl LSD	296.1757	C <sub>18</sub> H <sub>22</sub> N <sub>3</sub> O	3.3	223.1229	208.0756	253.1335
3	<i>N</i> <sup>6</sup> -Demethyl LSD	310.1913	C <sub>19</sub> H <sub>24</sub> N <sub>3</sub> O	5.3	209.1073	74.0964	237.1022
4	Hydroxy LSD isomer 1	340.2019	C <sub>20</sub> H <sub>26</sub> N <sub>3</sub> O <sub>2</sub>	3.4	221.1073	239.1184	322.1913
5	Hydroxy LSD isomer 2	340.2019	C <sub>20</sub> H <sub>26</sub> N <sub>3</sub> O <sub>2</sub>	3.6	239.1184	297.1597	224.0706
6	Dihydroxy LSD	356.1968	C <sub>20</sub> H <sub>26</sub> N <sub>3</sub> O <sub>3</sub>	2.5	237.1022	74.0964	313.1552
7	Hydroxy LSD isomer 2 glucuronide	516.2340	C <sub>26</sub> H <sub>34</sub> N <sub>3</sub> O <sub>8</sub>	2.0	239.1184	340.2019	224.0706
<b>8</b>	<b>ALD-52</b>	<b>366.2176</b>	<b>C<sub>22</sub>H<sub>28</sub>N<sub>3</sub>O<sub>2</sub></b>	<b>6.2</b>	<b>265.1335</b>	<b>223.1229</b>	<b>208.0756</b>
2	1-Deacetyl- <i>N</i> -deethyl ALD-52	296.1757	C <sub>18</sub> H <sub>22</sub> N <sub>3</sub> O	3.3	223.1229	208.0756	253.1335
3	1-Deacetyl- <i>N</i> <sup>6</sup> -demethyl ALD-52	310.1913	C <sub>19</sub> H <sub>24</sub> N <sub>3</sub> O	5.3	209.1073	74.0964	237.1022
1	1-Deacetyl ALD-52	324.2070	C <sub>20</sub> H <sub>26</sub> N <sub>3</sub> O	5.3	223.1229	208.0995	281.1648
9	<i>N</i> -Deethyl ALD-52	338.1863	C <sub>20</sub> H <sub>24</sub> N <sub>3</sub> O <sub>2</sub>	4.5	265.1335	223.1229	295.1441
4	1-Deacetyl-hydroxy ALD-52 isomer 1	340.2019	C <sub>20</sub> H <sub>26</sub> N <sub>3</sub> O <sub>2</sub>	3.4	221.1073	239.1184	322.1913
5	1-Deacetyl-hydroxy ALD-52 isomer 2	340.2019	C <sub>20</sub> H <sub>26</sub> N <sub>3</sub> O <sub>2</sub>	3.6	239.1184	297.1597	224.0706
10	<i>N</i> <sup>6</sup> -Demethyl ALD-52	352.2019	C <sub>21</sub> H <sub>26</sub> N <sub>3</sub> O <sub>2</sub>	6.2	251.1178	209.1073	74.0964
<b>11</b>	<b>1P-LSD</b>	<b>380.2332</b>	<b>C<sub>23</sub>H<sub>30</sub>N<sub>3</sub>O<sub>2</sub></b>	<b>7.2</b>	<b>223.1229</b>	<b>279.1491</b>	<b>208.0756</b>
2	1-Depropionyl- <i>N</i> -deethyl-1P-LSD	296.1757	C <sub>18</sub> H <sub>22</sub> N <sub>3</sub> O	3.3	223.1229	208.0756	253.1335
3	1-Depropionyl- <i>N</i> <sup>6</sup> -demethyl 1P-LSD	310.1913	C <sub>19</sub> H <sub>24</sub> N <sub>3</sub> O	5.3	209.1073	74.0964	237.1022
1	1-Depropionyl 1P-LSD	324.2070	C <sub>20</sub> H <sub>26</sub> N <sub>3</sub> O	5.3	223.1229	208.0995	281.1648
4	1-Depropionyl-hydroxy 1P-LSD isomer 1	340.2019	C <sub>20</sub> H <sub>26</sub> N <sub>3</sub> O <sub>2</sub>	3.4	221.1073	239.1184	322.1913
5	1-Depropionyl-hydroxy 1P-LSD isomer 2	340.2019	C <sub>20</sub> H <sub>26</sub> N <sub>3</sub> O <sub>2</sub>	3.6	239.1184	297.1597	224.0706
12	<i>N</i> -Deethyl 1P-LSD	352.2019	C <sub>21</sub> H <sub>26</sub> N <sub>3</sub> O <sub>2</sub>	5.6	223.1229	279.1491	208.0756
6	1-Depropionyl-dihydroxy 1P-LSD	356.1968	C <sub>20</sub> H <sub>26</sub> N <sub>3</sub> O <sub>3</sub>	2.5	237.1022	74.0964	313.1552
13	<i>N</i> <sup>6</sup> -Demethyl 1P-LSD	366.2176	C <sub>22</sub> H <sub>28</sub> N <sub>3</sub> O <sub>2</sub>	7.2	209.1073	265.1335	74.0964
<b>14</b>	<b>1B-LSD</b>	<b>394.2489</b>	<b>C<sub>24</sub>H<sub>32</sub>N<sub>3</sub>O<sub>2</sub></b>	<b>8.0</b>	<b>293.1648</b>	<b>223.1229</b>	<b>208.0756</b>
2	1-Debutyryl- <i>N</i> -deethyl-1B-LSD	296.1757	C <sub>18</sub> H <sub>22</sub> N <sub>3</sub> O	3.3	223.1229	208.0756	253.1335
3	1-Debutyryl- <i>N</i> <sup>6</sup> -demethyl 1B-LSD	310.1913	C <sub>19</sub> H <sub>24</sub> N <sub>3</sub> O	5.3	209.1073	74.0964	237.1022
1	1-Debutyryl 1B-LSD	324.2070	C <sub>20</sub> H <sub>26</sub> N <sub>3</sub> O	5.3	223.1229	208.0995	281.1648
4	1-Debutyryl-hydroxy 1B-LSD isomer 1	340.2019	C <sub>20</sub> H <sub>26</sub> N <sub>3</sub> O <sub>2</sub>	3.4	221.1073	239.1184	322.1913
5	1-Debutyryl-hydroxy 1B-LSD isomer 2	340.2019	C <sub>20</sub> H <sub>26</sub> N <sub>3</sub> O <sub>2</sub>	3.6	239.1184	297.1597	224.0706
6	1-Debutyryl-dihydroxy	356.1968	C <sub>20</sub> H <sub>26</sub> N <sub>3</sub> O <sub>3</sub>	2.5	237.1022	74.0964	313.1552

1							
2							
3		1B- LSD					
4	15	Hydroxy 1B-LSD	410.2438	C <sub>24</sub> H <sub>32</sub> N <sub>3</sub> O <sub>3</sub>	5.7	309.1597	223.1229 208.0995
5	16	<b>ETH-LAD</b>	<b>338.2226</b>	<b>C<sub>21</sub>H<sub>28</sub>N<sub>3</sub>O</b>	<b>5.6</b>	<b>237.1386</b>	<b>208.0995 309.1835</b>
6	17	<i>N</i> -Deethyl ETH-LAD	310.1913	C <sub>19</sub> H <sub>24</sub> N <sub>3</sub> O	3.6	237.1386	208.0995 281.1522
7	3	<i>N</i> <sup>6</sup> -Deethyl ETH-LAD	310.1913	C <sub>19</sub> H <sub>24</sub> N <sub>3</sub> O	5.3	209.1073	74.0964 237.1022
8	18	Hydroxy ETH-LAD	354.2176	C <sub>21</sub> H <sub>28</sub> N <sub>3</sub> O <sub>2</sub>	3.8	253.1335	297.1603 196.0762
9	19	Dihydroxy ETH-LAD	370.2125	C <sub>21</sub> H <sub>28</sub> N <sub>3</sub> O <sub>3</sub>	2.8	251.1178	279.1128 313.1552
10	20	Hydroxy ETH-LAD	530.2496	C <sub>27</sub> H <sub>36</sub> N <sub>3</sub> O <sub>8</sub>	2.4	253.1335	354.2176 325.1784
11		glucuronide					
12	21	<b>1P-ETH-LAD</b>	<b>394.2489</b>	<b>C<sub>24</sub>H<sub>32</sub>N<sub>3</sub>O<sub>2</sub></b>	<b>7.6</b>	<b>293.1648</b>	<b>237.1386 208.0756</b>
13	17	1-Depropionyl- <i>N</i> -deethyl	310.1913	C <sub>19</sub> H <sub>24</sub> N <sub>3</sub> O	3.6	237.1386	208.0995 281.1522
14		1P-ETH-LAD					
15	3	1-Depropionyl- <i>N</i> <sup>6</sup> -	310.1913	C <sub>19</sub> H <sub>24</sub> N <sub>3</sub> O	5.3	209.1073	74.0964 237.1022
16		deethyl 1P-ETH-LAD					
17	16	1-Depropionyl 1P-ETH-	338.2226	C <sub>21</sub> H <sub>28</sub> N <sub>3</sub> O	5.6	237.1386	208.0995 309.1835
18		LAD					
19	18	1-Depropionyl-hydroxy	354.2176	C <sub>21</sub> H <sub>28</sub> N <sub>3</sub> O <sub>2</sub>	3.8	253.1335	297.1603 196.0762
20		1P-ETH-LAD					
21	22	<i>N</i> -Deethyl 1P-ETH-LAD	366.2176	C <sub>22</sub> H <sub>28</sub> N <sub>3</sub> O <sub>2</sub>	5.9	293.1648	208.0995 237.1648
22	19	1-Depropionyl-	370.2125	C <sub>21</sub> H <sub>28</sub> N <sub>3</sub> O <sub>3</sub>	2.8	251.1178	279.1128 313.1552
23		dihydroxy 1P-ETH-LAD					
24	20	1-Depropionyl-hydroxy	530.2496	C <sub>27</sub> H <sub>36</sub> N <sub>3</sub> O <sub>8</sub>	2.4	253.1335	354.2176 325.1784
25		1P-ETH-LAD					
26		glucuronide					
27	23	<b>AL-LAD</b>	<b>350.2226</b>	<b>C<sub>22</sub>H<sub>28</sub>N<sub>3</sub>O</b>	<b>6.2</b>	<b>208.0995</b>	<b>309.1835 182.0838</b>
28	24	<i>N</i> <sup>6</sup> -Deallyl- <i>N</i> -deethyl	282.1600	C <sub>17</sub> H <sub>20</sub> N <sub>3</sub> O	3.2	209.1073	237.1027 134.0964
29		AL-LAD					
30	25	<i>N</i> <sup>6</sup> -Allyl-norlysergic acid	295.1441	C <sub>18</sub> H <sub>19</sub> N <sub>2</sub> O <sub>2</sub>	2.9	70.0656	254.1049 238.0868
31	3	<i>N</i> <sup>6</sup> -Deallyl AL-LAD	310.1913	C <sub>19</sub> H <sub>24</sub> N <sub>3</sub> O	5.3	209.1073	74.0964 237.1022
32	26	<i>N</i> -Deethyl AL-LAD	322.1913	C <sub>20</sub> H <sub>24</sub> N <sub>3</sub> O	4.2	281.1522	208.0995 182.0838
33	27	<i>N</i> -Deethyl-hydroxy AL-	338.1863	C <sub>20</sub> H <sub>24</sub> N <sub>3</sub> O <sub>2</sub>	2.6	297.1471	225.1022 207.0916
34		LAD					
35	28	Hydroxy AL-LAD	366.2176	C <sub>22</sub> H <sub>28</sub> N <sub>3</sub> O <sub>2</sub>	3.8	224.0944	325.1784 198.0787
36		isomer 1					
37	29	Hydroxy AL-LAD	366.2176	C <sub>22</sub> H <sub>28</sub> N <sub>3</sub> O <sub>2</sub>	4.3	223.0871	325.1784 297.1603
38		isomer 2					
39	30	Hydroxy AL-LAD	366.2176	C <sub>22</sub> H <sub>28</sub> N <sub>3</sub> O <sub>2</sub>	5.0	207.0922	247.1235 265.1340
40		isomer 3					
41	31	Dihydroxy AL-LAD	382.2125	C <sub>22</sub> H <sub>28</sub> N <sub>3</sub> O <sub>3</sub>	3.3	221.0714	263.1178 313.1552
42		isomer 1					
43	32	Dihydroxy AL-LAD	382.2125	C <sub>22</sub> H <sub>28</sub> N <sub>3</sub> O <sub>3</sub>	4.1	128.1069	255.1133 223.0871
44		isomer 2					
45	33	Hydroxy AL-LAD	542.2496	C <sub>28</sub> H <sub>36</sub> N <sub>3</sub> O <sub>8</sub>	3.1	325.1784	224.0944 501.2105
46		isomer 1 glucuronide					
47	34	<b>ECPLA</b>	<b>336.2070</b>	<b>C<sub>21</sub>H<sub>26</sub>N<sub>3</sub>O</b>	<b>6.0</b>	<b>223.1235</b>	<b>208.0756 86.0964</b>
48	35	Lysergic acid amide	268.1444	C <sub>16</sub> H <sub>18</sub> N <sub>3</sub> O	1.5	223.1235	208.0762 180.0813
49	36	Lysergic acid	269.1284	C <sub>16</sub> H <sub>17</sub> N <sub>2</sub> O <sub>2</sub>	2.2	223.1235	254.1049 238.0868
50	37	<i>N</i> -Deethyl ECPLA	308.1757	C <sub>19</sub> H <sub>22</sub> N <sub>3</sub> O	3.3	223.1235	208.0762 265.1340
51	38	<i>N</i> <sup>6</sup> -Demethyl ECPLA	322.1913	C <sub>20</sub> H <sub>24</sub> N <sub>3</sub> O	5.9	209.1078	237.1027 86.0964
52		Hydroxy ECPLA					
53	39	isomer 1	352.2019	C <sub>21</sub> H <sub>26</sub> N <sub>3</sub> O <sub>2</sub>	3.0	239.1184	224.0944 86.0964
54		Hydroxy ECPLA					
55	40	isomer 2	352.2019	C <sub>21</sub> H <sub>26</sub> N <sub>3</sub> O <sub>2</sub>	4.0	239.1184	221.1078 334.1913
56							

41	Hydroxy ECPLA isomer 3	352.2019	C <sub>21</sub> H <sub>26</sub> N <sub>3</sub> O <sub>2</sub>	4.2	239.1184	86.0964	224.0706
42	Dihydroxy ECPLA	368.1968	C <sub>21</sub> H <sub>26</sub> N <sub>3</sub> O <sub>3</sub>	3.3	237.1027	222.0555	86.0964
<b>43</b>	<b>LSZ</b>	<b>336.2070</b>	<b>C<sub>21</sub>H<sub>26</sub>N<sub>3</sub>O</b>	<b>5.3</b>	<b>223.1235</b>	<b>140.1070</b>	<b>208.0995</b>
35	Lysergic acid amide	268.1444	C <sub>16</sub> H <sub>18</sub> N <sub>3</sub> O	1.5	223.1235	208.0762	180.0813
36	Lysergic acid	269.1284	C <sub>16</sub> H <sub>17</sub> N <sub>2</sub> O <sub>2</sub>	2.2	223.1235	254.1049	238.0868
44	Hydroxy lysergic acid amide	284.1393	C <sub>16</sub> H <sub>18</sub> N <sub>3</sub> O <sub>2</sub>	1.0	221.1078	266.1287	239.1184
45	N <sup>6</sup> -Demethyl LSZ	322.1913	C <sub>20</sub> H <sub>24</sub> N <sub>3</sub> O	5.2	209.1073	140.1070	237.1027
46	Hydroxy LSZ isomer 1	352.2019	C <sub>21</sub> H <sub>26</sub> N <sub>3</sub> O <sub>2</sub>	3.7	239.1184	224.0711	140.1070
47	Hydroxy LSZ isomer 2	352.2019	C <sub>21</sub> H <sub>26</sub> N <sub>3</sub> O <sub>2</sub>	3.9	221.1078	334.1913	249.1027
48	Hydroxy LSZ isomer 3	352.2019	C <sub>21</sub> H <sub>26</sub> N <sub>3</sub> O <sub>2</sub>	4.3	208.0762	223.1235	334.1913
49	Dihydroxy LSZ	368.1968	C <sub>21</sub> H <sub>26</sub> N <sub>3</sub> O <sub>3</sub>	2.8	237.1027	222.0555	265.0977
50	Hydroxy LSZ isomer 1 glucuronide	528.2340	C <sub>27</sub> H <sub>34</sub> N <sub>3</sub> O <sub>8</sub>	2.1	239.1184	352.2019	140.1070
<b>51</b>	<b>LSM-775</b>	<b>338.1863</b>	<b>C<sub>20</sub>H<sub>24</sub>N<sub>3</sub>O<sub>2</sub></b>	<b>3.5</b>	<b>223.1235</b>	<b>208.0762</b>	<b>295.1446</b>
52	N <sup>6</sup> -Demethyl LSM-775	324.1706	C <sub>19</sub> H <sub>22</sub> N <sub>3</sub> O <sub>2</sub>	3,4	209.1078	237.1027	183.0922
53	Hydroxy LSM-775 isomer 1	354.1812	C <sub>20</sub> H <sub>24</sub> N <sub>3</sub> O <sub>3</sub>	1.5	221.1078	336.1706	249.1027
54	Hydroxy LSM-775 isomer 2	354.1812	C <sub>20</sub> H <sub>24</sub> N <sub>3</sub> O <sub>3</sub>	1.7	221.1078	336.1706	249.1027
55	Hydroxy LSM-775 isomer 3	354.1812	C <sub>20</sub> H <sub>24</sub> N <sub>3</sub> O <sub>3</sub>	2.1	239.1184	224.0706	311.1395

**Table 2:** General involvement of tested monooxygenases in the initial metabolic steps. n.d. = not detected

Compound	<i>N</i> <sup>6</sup> -Dealkylation	<i>N</i> -Deethylation	Hydroxylation
LSD	CYP2C19	CYP2C9	CYP1A2
	CYP3A4	CYP3A4	CYP3A4
ALD-52	CYP3A4	CYP3A4	CYP2D6
			CYP3A4
1P-LSD	CYP3A4	CYP3A4	CYP3A4
1B-LSD	CYP3A4	CYP3A4	CYP2D6
			CYP3A4
ETH-LAD	CYP3A4	CYP3A4	CYP2D6
			CYP3A4
1P-ETH-LAD	CYP3A4	CYP3A4	CYP3A4
AL-LAD	CYP3A4	CYP3A4	CYP1A2
			CYP3A4
ECPLA	CYP2C19	CYP2C9	CYP1A2
	CYP3A4	CYP3A4	CYP3A4
LSZ	CYP3A4	n.d.	CYP1A2
			CYP3A4
LSM-775	CYP3A4	n.d.	CYP1A2
			CYP3A4

## References

1. Stevens J. *Storming Heaven: LSD and the American dream*. New York: Grove Press; 1987.
2. Hoffman AJ, Nichols DE. Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. *J Med Chem*. 1985;28(9):1252-5.
3. Oberlender R, Pfaff RC, Johnson MP, Huang XM, Nichols DE. Stereoselective LSD-like activity in d-lysergic acid amides of (R)- and (S)-2-aminobutane. *J Med Chem*. 1992;35(2):203-11.
4. Huang X, Marona-Lewicka D, Pfaff RC, Nichols DE. Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives. *Pharmacol Biochem Behav*. 1994;47(3):667-73.
5. Monte AP, Marona-Lewicka D, Kanthasamy A, Sanders-Bush E, Nichols DE. Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes. *J Med Chem*. 1995;38(6):958-66.
6. Nichols DE, Frescas S, Marona-Lewicka D, Kurrasch-Orbaugh DM. Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD). *J Med Chem*. 2002;45(19):4344-9.
7. Shulgin A, Shulgin A. *Tihkal: The Continuation*. Transform Press, Berkley (CA). 1997.
8. Pfaff RC, Huang X, Marona-Lewicka D, Oberlender R, Nichols DE. Lysergamides revisited. *NIDA Res Monogr*. 1994;146:52-73.
9. Nichols DE. LSD and its lysergamide cousins. *Heffter Rev Psychedelic Res*. 2001;2:80-7.
10. Nichols DE. Psychedelics. *Pharmacol Rev*. 2016;68(2):264-355.
11. Nichols DE. Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD). *ACS Chem Neurosci*. 2018;9(10):2331-43.
12. Liechti ME. Modern Clinical Research on LSD. *Neuropsychopharmacology*. 2017;42(11):2114-27.
13. Brandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Hoang K et al. Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD). *Drug Test Anal*. 2016;8(9):891-902.
14. Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Stratford A et al. Return of the lysergamides. Part III: Analytical characterization of N(6)-ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD). *Drug Test Anal*. 2017;9(10):1641-9.

15. Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Colestock T et al. Return of the lysergamides. Part II: Analytical and behavioural characterization of N(6) -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ). *Drug Test Anal.* 2017;9(1):38-50.
16. Halberstadt AL, Klein LM, Chatha M, Valenzuela LB, Stratford A, Wallach J et al. Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA). *Psychopharmacology (Berl)*. 2018.
17. Brandt SD, Kavanagh PV, Twamley B, Westphal F, Elliott SP, Wallach J et al. Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775). *Drug Test Anal.* 2017.
18. EMCDDA. European Drug Report 2017: Trends and Developments. Publications of the European Union 2017.
19. Canezin J, Cailleux A, Turcant A, Le Bouil A, Harry P, Allain P. Determination of LSD and its metabolites in human biological fluids by high-performance liquid chromatography with electrospray tandem mass spectrometry. *J Chromatogr B Biomed Sci Appl.* 2001;765(1):15-27.
20. Dolder PC, Liechti ME, Rentsch KM. Development and validation of a rapid turboflow LC-MS/MS method for the quantification of LSD and 2-oxo-3-hydroxy LSD in serum and urine samples of emergency toxicological cases. *Anal Bioanal Chem.* 2015;407(6):1577-84.
21. Dolder PC, Schmid Y, Haschke M, Rentsch KM, Liechti ME. Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans. *Int J Neuropsychopharmacol.* 2015;19(1).
22. Diao X, Huestis MA. Approaches, Challenges, and Advances in Metabolism of New Synthetic Cannabinoids and Identification of Optimal Urinary Marker Metabolites. *Clin Pharmacol Ther.* 2017;101(2):239-53.
23. Welter-Luedeke J, Maurer HH. New Psychoactive Substances: Chemistry, Pharmacology, Metabolism, and Detectability of Amphetamine Derivatives With Modified Ring Systems. *Ther Drug Monit.* 2016;38(1):4-11.
24. Meyer MR. New psychoactive substances: an overview on recent publications on their toxicodynamics and toxicokinetics. *Arch Toxicol.* 2016;90(10):2421-44.
25. Meyer MR. Toxicokinetics of NPS: Update 2017. *Handb Exp Pharmacol.* 2018.
26. Mogler L, Wilde M, Huppertz LM, Weinfurter G, Franz F, Auwarter V. Phase I metabolism of the recently emerged synthetic cannabinoid CUMYL-PEGACLONE and detection in human urine samples. *Drug Test Anal.* 2018.
27. Watanabe S, Vikingsson S, Roman M, Green H, Kronstrand R, Wohlfarth A. In Vitro and In Vivo Metabolite Identification Studies for the New Synthetic Opioids Acetylfentanyl, Acrylfentanyl, Furanylfentanyl, and 4-Fluoro-Isobutyrylfentanyl. *AAPS J.* 2017;19(4):1102-22.

- 1  
2  
3 28. Welter J, Meyer MR, Wolf EU, Weinmann W, Kavanagh P, Maurer HH. 2-  
4 methiopropamine, a thiophene analogue of methamphetamine: studies on its  
5 metabolism and detectability in the rat and human using GC-MS and LC-(HR)-MS  
6 techniques. *Anal Bioanal Chem.* 2013;405(10):3125-35.  
7  
8  
9 29. Richter LHJ, Flockerzi V, Maurer HH, Meyer MR. Pooled human liver  
10 preparations, HepaRG, or HepG2 cell lines for metabolism studies of new  
11 psychoactive substances? A study using MDMA, MDBD, butylone, MDPPP, MDPV,  
12 MDPB, 5-MAPB, and 5-API as examples. *J Pharm Biomed Anal.* 2017;143:32-42.  
13  
14 30. Chauret N, Gauthier A, Nicoll-Griffith DA. Effect of common organic solvents on  
15 in vitro cytochrome P450-mediated metabolic activities in human liver microsomes.  
16 *Drug Metab Dispos.* 1998;26(1):1-4.  
17  
18 31. Wagmann L, Meyer MR, Maurer HH. What is the contribution of human FMO3 in  
19 the N-oxygenation of selected therapeutic drugs and drugs of abuse? *Toxicol Lett.*  
20 2016;258:55-70.  
21  
22 32. Meyer GM, Meyer MR, Wink CS, Zapp J, Maurer HH. Studies on the in vivo  
23 contribution of human cytochrome P450s to the hepatic metabolism of glaucine, a  
24 new drug of abuse. *Biochem Pharmacol.* 2013;86(10):1497-506.  
25  
26 33. Wagmann L, Brandt SD, Kavanagh PV, Maurer HH, Meyer MR. In vitro  
27 monoamine oxidase inhibition potential of alpha-methyltryptamine analog new  
28 psychoactive substances for assessing possible toxic risks. *Toxicol Lett.*  
29 2017;272:84-93.  
30  
31 34. Welter J, Kavanagh P, Meyer MR, Maurer HH. Benzofuran analogues of  
32 amphetamine and methamphetamine: studies on the metabolism and toxicological  
33 analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-  
34 MS(n) techniques. *Anal Bioanal Chem.* 2015;407(5):1371-88.  
35  
36 35. Helfer AG, Michely JA, Weber AA, Meyer MR, Maurer HH. Orbitrap technology  
37 for comprehensive metabolite-based liquid chromatographic-high resolution-tandem  
38 mass spectrometric urine drug screening - exemplified for cardiovascular drugs. *Anal*  
39 *Chim Acta.* 2015;891:221-33.  
40  
41 36. Caspar AT, Westphal F, Meyer MR, Maurer HH. LC-high resolution-MS/MS for  
42 identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl)-  
43 N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and  
44 human liver S9 incubates and comparison of its screening power with further MS  
45 techniques. *Anal Bioanal Chem.* 2018;410(3):897-912.  
46  
47 37. Wissenbach DK, Meyer MR, Remane D, Philipp AA, Weber AA, Maurer HH.  
48 Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening  
49 concept. *Anal Bioanal Chem.* 2011;400(10):3481-9.  
50  
51 38. Meyer MR, Lindauer C, Welter J, Maurer HH. Dimethocaine, a synthetic cocaine  
52 analogue: studies on its in-vivo metabolism and its detectability in urine by means of  
53 a rat model and liquid chromatography-linear ion-trap (high-resolution) mass  
54 spectrometry. *Anal Bioanal Chem.* 2014;406(7):1845-54.  
55  
56  
57  
58  
59  
60



- 1  
2  
3 39. Maurer HH, Pflieger K, Weber AA. Mass spectral data of drugs, poisons,  
4 pesticides, pollutants and their metabolites. Weinheim: Wiley-VCH; 2016.  
5  
6 40. Klette KL, Anderson CJ, Poch GK, Nimrod AC, ElSohly MA. Metabolism of  
7 lysergic acid diethylamide (LSD) to 2-oxo-3-hydroxy LSD (O-H-LSD) in human liver  
8 microsomes and cryopreserved human hepatocytes. *J Anal Toxicol.* 2000;24(7):550-  
9 6.  
10  
11 41. Poch GK, Klette KL, Hallare DA, Manglicmot MG, Czarny RJ, McWhorter LK et  
12 al. Detection of metabolites of lysergic acid diethylamide (LSD) in human urine  
13 specimens: 2-oxo-3-hydroxy-LSD, a prevalent metabolite of LSD. *J Chromatogr B*  
14 *Biomed Sci Appl.* 1999;724(1):23-33.  
15  
16 42. Steuer AE, Poetzsch M, Stock L, Eisenbeiss L, Schmid Y, Liechti ME et al.  
17 Development and validation of an ultra-fast and sensitive microflow liquid  
18 chromatography-tandem mass spectrometry (MFLC-MS/MS) method for  
19 quantification of LSD and its metabolites in plasma and application to a controlled  
20 LSD administration study in humans. *Drug Test Anal.* 2017;9(5):788-97.  
21  
22 43. Dolder PC, Liechti ME, Rentsch KM. Development and validation of an LC-  
23 MS/MS method to quantify lysergic acid diethylamide (LSD), iso-LSD, 2-oxo-3-  
24 hydroxy-LSD, and nor-LSD and identify novel metabolites in plasma samples in a  
25 controlled clinical trial. *J Clin Lab Anal.* 2018;32(2).  
26  
27 44. Favretto D, Frison G, Maietti S, Ferrara SD. LC-ESI-MS/MS on an ion trap for the  
28 determination of LSD, iso-LSD, nor-LSD and 2-oxo-3-hydroxy-LSD in blood, urine  
29 and vitreous humor. *Int J Legal Med.* 2007;121(4):259-65.  
30  
31 45. Jang M, Kim J, Han I, Yang W. Simultaneous determination of LSD and 2-oxo-3-  
32 hydroxy LSD in hair and urine by LC-MS/MS and its application to forensic cases. *J*  
33 *Pharm Biomed Anal.* 2015;115:138-43.  
34  
35 46. Johansen SS, Jensen JL. Liquid chromatography-tandem mass spectrometry  
36 determination of LSD, ISO-LSD, and the main metabolite 2-oxo-3-hydroxy-LSD in  
37 forensic samples and application in a forensic case. *J Chromatogr B Analyt Technol*  
38 *Biomed Life Sci.* 2005;825(1):21-8.  
39  
40 47. Richter LHJ, Maurer HH, Meyer MR. New psychoactive substances: Studies on  
41 the metabolism of XLR-11, AB-PINACA, FUB-PB-22, 4-methoxy-alpha-PVP, 25-I-  
42 NBOMe, and meclonazepam using human liver preparations in comparison to  
43 primary human hepatocytes, and human urine. *Toxicol Lett.* 2017;280:142-50.  
44  
45 48. Niessen WM, Correa RA. Interpretation of MS-MS Mass Spectra of Drugs and  
46 Pesticides. Hoboken, New Jersey: John Wiley & Sons; 2016.  
47  
48 49. Wink CS, Meyer GM, Meyer MR, Maurer HH. Toxicokinetics of lefetamine and  
49 derived diphenylethylamine designer drugs-Contribution of human cytochrome P450  
50 isozymes to their main phase I metabolic steps. *Toxicol Lett.* 2015;238(3):39-44.  
51  
52 50. Koonrungsesomboon N, Khatsri R, Wongchompoo P, Teekachunhatean S. The  
53 impact of genetic polymorphisms on CYP1A2 activity in humans: a systematic review  
54 and meta-analysis. *Pharmacogenomics J.* 2017.  
55  
56  
57  
58  
59  
60

- 1  
2  
3 51. Nichols DE, Grob CS. Is LSD toxic? *Forensic Sci Int.* 2018;284:141-5.  
4  
5 52. Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. The pharmacology  
6 of lysergic acid diethylamide: a review. *CNS Neurosci Ther.* 2008;14(4):295-314.  
7  
8 53. Sharma V, McNeill JH. To scale or not to scale: the principles of dose  
9 extrapolation. *Br J Pharmacol.* 2009;157(6):907-21.  
10  
11 54. Crews C. *Analysis of Ergot Alkaloids. Toxins (Basel).* 2015;7(6):2024-50.  
12  
13 55. Meyer MR, Schmitt S, Maurer HH. Studies on the metabolism and detectability of  
14 the emerging drug of abuse diphenyl-2-pyrrolidinemethanol (D2PM) in rat urine using  
15 GC-MS and LC-HR-MS/MS. *J Mass Spectrom.* 2013;48(2):243-9.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review


## Legends to the figures

**Fig. 1:** Chemical structures of LSD and nine LSD-based new psychoactive substances. Structural changes in comparison to LSD are marked in red.


**Fig. 2:** HRMS/MS spectra and retention times (RT) of LSD (ID 1) and 1P-LSD (ID 11) as well as two of their metabolites (hydroxy LSD isomer 1, ID 4 and *N*-deethyl 1P-LSD, ID 12) to support described mass spectral based metabolite identification. Numbering according to Table 1.

**Fig. 3:** Postulated metabolic pathways of 1P-LSD studied by in vitro incubations with pooled human liver S9 fraction. Numbering according to Table 1.


**Fig. 4:** Percentage formation of CYP-dependent metabolites in pHLM co-incubations of LSD or LSD analogs with the selective CYP1A2 inhibitor alpha-naphthoflavone, the selective CYP3A4 inhibitor ketoconazole, or a mixture of both inhibitors. Formation in reference incubations without inhibitor was referred to as 100%.




ETH-LAD




LSM-775




1B-LSD




LSZ




1P-LSD




ECPLA




ALD-52



AL-LAD








LSD




1P-ETH-LAD

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 **Analytical and Bioanalytical Chemistry**  
4  
5





6 **Electronic Supplementary Material**  
7  
8  
9

10 **In vitro metabolic fate of nine LSD-based new psychoactive substances and**  
11 **their analytical detectability in different urinary screening procedures**  
12  
13  
14

15  
16  
17  
18 Lea Wagmann, Lilian H. J. Richter, Tobias Kehl, Franziska Wack, Madeleine  
19 Pettersson Bergstrand, Simon D. Brandt, Alexander Stratford, Hans H. Maurer,  
20 and Markus R. Meyer  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review





54  
55  
56  
57  
58  
59  
60

Fig. S1: HRMS/MS spectra of LSD-based new psychoactive substances and their most abundant, unique metabolites along with their retention times (RT). Numbering according to Table 1 in the manuscript.







Fig. S1 (continued)







Fig. S1 (continued)







Fig. S1 (continued)




Fig. S2: Metabolic pathways of LSD studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.




Fig. S3: Metabolic pathways of ALD-52 studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.




Fig. S4: Metabolic pathways of 1B-LSD studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.




Fig. S5: Metabolic pathways of ETH-LAD studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.






Fig. S6: Metabolic pathways of 1P-ETH-LAD studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.




Fig. S7: Metabolic pathways of AL-LAD studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.




Fig. S8: Metabolic pathways of ECPLA studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.





Fig. S9: Metabolic pathways of LSZ studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.



16 Fig. S10: Metabolic pathways of LSM-775 studied in incubations with pooled human liver S9  
17 fraction. Numbering according to Table 1 in the manuscript.  
18  
19

20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review